<i>In Vitro</i>
            Activity of Posaconazole against Talaromyces marneffei by Broth Microdilution and Etest Methods and Comparison to Itraconazole, Voriconazole, and Anidulafungin

Lau, Susanna K.P.; Lo, George C.S.; Lam, Clare S.K.; Chow, Wang Ngai; Ngan, Antonio H. Y.; Wu, Alan Ka-Lun; Tsang, Dominic N.C.; Tse, Cindy Wing-Sze; Que, Tak Lun; Tang, Bone Siu-Fai; Woo, Patrick C. Y.

doi:10.1128/aac.01480-16

Cited by 25 publications

(38 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Itraconazole, amphotericin B and voriconazole are effective in treating talaromycosis marneffei [5, 6]. Pulmonary LELC is sensitive to paclitaxel- or docetaxel-based regimens [7] and apatinib can be used as a third-line treatment for EGFR wild-type advanced non-small cell lung cancer [8].…”

Section: Discussionmentioning

confidence: 99%

Talaromyces marneffei infection in a lung cancer patient: a rare case report

et al. 2019

View full text Add to dashboard Cite

Background Talaromyces marneffei is an invasive, and thermal dimorphic pathogenic fungus, whose infection is life threatening in human . Although immunocompromised patients, such as patients with human immunodeficiency virus infection and recipients of organ transplant, are susceptible hosts, infections have been recently reported in people with normal immune function. Patients with cancer may also be susceptible hosts but no case of T. marneffei infection has been reported in patients with lung cancer. In this case, we describe T. marneffei infection coexisting with primary pulmonary lymphoepithelioma-like carcinoma (LELC) in an HIV-negative patient. Case presentation A 50-year-old, previously healthy female presented with a 1-month history of cough and fever. CT scans showed a mass in the left lower lung, left pleural thickening, pleural effusion, and multiple swollen lymph nodes throughout the body. Based on the pathology of the left lung lesion, she was diagnosed with left primary pulmonary LELC complicated with T. marneffei . She received both anti-tumor and anti-fungal treatments. A subsequent CT re-examination demonstrated that the mass was absorbed remarkably after treatment. Follow up showed no tumor progression and no relapse of T. marneffei infection. Conclusion This case suggested that clinicians should pay more attention to the potential hosts of T. marneffei infection, especially those with lung cancer. Early diagnosis and treatment can improve the prognosis of T. marneffei infection coexisting with lung cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Talaromyces marneffei infection in a lung cancer patient: a rare case report

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Amphotericin B, itraconazole, and voriconazole are effective in treating Talaromycosis [10]. The recommended dosage and duration of treatment for HIVinfected adult patients are intravenous amphotericin B deoxycholate 0.6-1.0 mg/kg/day for 2 weeks, followed by oral itraconazole 400 mg/day for 8-10 weeks [11].…”

Section: Discussionmentioning

confidence: 99%

Disseminated Talaromyces marneffei infection presenting as multiple intestinal perforations and diffuse hepatic granulomatous inflammation in an infant with STAT3 mutation: a case report

et al. 2020

View full text Add to dashboard Cite

Background: Talaromyces marneffei is a highly pathogenic fungus that can cause life-threatening fatal systemic mycosis. Disseminated Talaromycosis marneffei affects multiple organs, including the lungs, skin, and reticuloendothelial system. However, T. marneffei infection has rarely been reported in human immunodeficiency virus (HIV)-negative infants with multiple intestinal perforations and diffuse hepatic granulomatous inflammation. Case presentation: We present the case of an HIV-negative 37-month-old boy who has had recurrent pneumonia since infancy and was infected with disseminated Talaromycosis. Contrast-enhanced computed tomography of the whole abdomen showed hepatomegaly and intestinal wall thickening in the ascending colon and cecum with mesenteric lymphadenopathy. Colonoscopy showed a cobblestone pattern with erosion, ulcer, polypoid lesions, and lumen deformation ranging from the colon to the cecum. T. marneffei was isolated from the mucous membrane of the colon, liver, and bone marrow. After antifungal treatment and surgery, his clinical symptoms significantly improved. Whole-exome sequencing using the peripheral blood of the patient and his parents' revealed a heterozygous missense mutation in exon 17 of the STAT3 gene (c.1673G>A, p.G558D). Conclusions: In T. marneffei infection-endemic areas, endoscopic examination, culture, or histopathology from the intestine tissue should be performed in disseminated Talaromycosis patients with gastrointestinal symptoms. Timely and systemic antifungal therapy could improve the prognosis. Immunodeficiency typically should be considered in HIV-negative infants with opportunistic infections.

show abstract

“…Posaconazole and isavuconazole, two triazoles with broad antifungal activities, may offer additional advantages over itraconazole and voriconazole especially in critically ill patients with organ dysfunction, as no renal or hepatic dosage adjustment is required. Recently, we reported promising activities of posaconazole against T. marneffei . In this study, we observed that the activity of isavuconazole is comparable to posaconazole against the seven T. marneffei strains.…”

Section: Discussionmentioning

confidence: 99%

“…In 2007, we described a multilocus sequence typing (MLST) scheme for T. marneffei and characterised the strains in Hong Kong . Recently, we also reported the use of matrix‐assisted laser desorption ionisation–time‐of‐flight mass spectrometry (MALDI–TOF MS) for identification of T. marneffei and the susceptibilities of T. marneffei strains from Hong Kong against amphotericin B, itraconazole, posaconazole and voriconazole . In this study, we report the clinical characteristics, molecular epidemiology, rapid identification and antifungal susceptibilities of T. marneffei infections in Shenzhen, a Southern Chinese metropolitan city with a large immigrant population from other parts of China.…”

Section: Introductionmentioning

confidence: 99%

Clinical characteristics, rapid identification, molecular epidemiology and antifungal susceptibilities of Talaromyces marneffei infections in Shenzhen, China

Lau

Xing

Tsang

et al. 2019

Mycoses

Self Cite

View full text Add to dashboard Cite

Summary Although case series of talaromycosis have been reported in China, their detailed clinical and microbiological characteristics have never been systematically profiled. In this study, we report the clinical characteristics, molecular epidemiology, rapid identification and antifungal susceptibilities of talaromycosis in The University of Hong Kong‐Shenzhen Hospital in Shenzhen. Seven cases of talaromycosis were observed since commencement of hospital service in 2012. Three patients were local Shenzhen residents, whereas the other four were immigrants from other parts of China. Two patients were HIV‐negative, but with underlying diseases requiring immunosuppressive therapy. Two of the seven patients succumbed. All the seven isolates were successfully identified as T. marneffei by MALDI–TOF MS using Bruker database expanded with in‐house generated T. marneffei mass spectra. MLST showed that the seven strains belonged to six different, novel sequences types. Phylogenetic analyses of the concatenated five‐locus sequence revealed that the seven strains were scattered amongst other T. marneffei strains. The MICs of itraconazole, isavuconazole, posaconazole and voriconazole against the seven clinical isolates were low but MICs of anidulafungin were high. Underlying diseases other than HIV infection are increasingly important risk factors of talaromycosis. MALDI–TOF MS is useful for rapid identification. Highly diverse T. marneffei sequence types were observed.

show abstract

In Vitro Activity of Posaconazole against Talaromyces marneffei by Broth Microdilution and Etest Methods and Comparison to Itraconazole, Voriconazole, and Anidulafungin

Cited by 25 publications

References 18 publications

Talaromyces marneffei infection in a lung cancer patient: a rare case report

Talaromyces marneffei infection in a lung cancer patient: a rare case report

Disseminated Talaromyces marneffei infection presenting as multiple intestinal perforations and diffuse hepatic granulomatous inflammation in an infant with STAT3 mutation: a case report

Clinical characteristics, rapid identification, molecular epidemiology and antifungal susceptibilities of Talaromyces marneffei infections in Shenzhen, China

Contact Info

Product

Resources

About